Developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.
A Unique Ecosystem for Medical Device Innovation & Value Creation
First-in-class treatment for disorders of the nervous system using small molecules
Targeting the WNT pathway to treat spinal cord injury (SCI), traumatic brain injury and stroke.
Developing therapeutics targeting mitochondrial pathways for brain disorders particularly in neuro degenerative diseases.
Leader of innovative topical medication, focusing to becoming global first-in-class drug discovery company in ophthalmology and dermatology. Dry eye (LFA1) & Eczema (PDE4) are two main projects of Viva Vision Biotech’s research, they have large potential market share and competitive advantages. The future product line will be first-in-class drugs to cover skin inflammation, bald spot diseases, glaucoma, etc.
New drugs for flu treatment
Develop influenza virus RNA polymerase nucleic acid endoenzyme (Endonuclease) inhibitor to treat influenza with high potency
Wei Qing biology
Targeting advanced cancers by combining tumor-autonomous approaches with immune stimulation
Build a convenient, accurate and real-time global health detection platform with the new generation a leading biochip micro measurement technology
Using SPR technology to build a technology platform and develop products for scientific research, medical and household